姣忔湀鑽墿蹇-2014骞?鏈圏/h1>
鏃堕棿锛?014-6-30 11:28:47
LONSURF 澶嶆柟鐗囨寜璁″垝鍦ㄦ棩鏈帹鍑
Taiho Pharmaceutical 鍏徃宸茬粡璇佸疄鍙f湇鏍歌嫹绫绘姉鐧岃嵂 Lonsurf(R)锛堜笁姘熻兏鑻?鐩愰吀tipiracil锛汿AS-102锛夎銆婂叏鍥藉尰淇濇姤閿€浠锋牸鐩綍銆嬫敹褰曪紝璁″垝灏嗕簬 5 鏈 26 鏃ュ湪鏃ユ湰鎺ㄥ嚭銆傛牴鎹湪鏃ユ湰瀹炴柦鐨 II 鏈熻瘯楠岀粨鏋滐紝Taiho 鍏徃 3 鏈堜唤鑾锋壒鍦ㄦ棩鏈鍏堢敓浜ч攢鍞紝鐢ㄤ簬涓嶅彲鍒囬櫎鏅氭湡鎴栧鍙戞€х粨鐩磋偁鐧岀殑閫傚簲鐥囷紙鍙湁鏍囧噯娌荤枟闅句互濂忔晥鏃讹級锛堣 2014 骞 3 鏈 24 鏃ャ€婃堡妫矾閫忚嵂鐗╂柊闂汇€嬶級銆傞毦娌绘€ц浆绉绘€х粨鐩磋偁鐧屾偅鑰呯殑涓€椤瑰叏鐞冩€ III 鏈熻瘯楠岋紙RECOURSE锛夎〃鏄庯紝TAS-102 缁勭殑鎬荤敓瀛樼巼锛堣璇曢獙鐨勪富瑕佺粓鐐癸級杈冨畨鎱板墏缁勬槑鏄炬敼鍠勶紙ClinicalTrials.gov 鏍囪瘑鍙 NCT01607957锛夈€傝鍏徃姝h鍒掑湪缇庡浗鍜屾娲插姹傜洃绠℃壒鍑嗭紙Taiho Pharmaceutical 鏂伴椈绋匡級銆
BMS 鍏徃鍏竷娌荤枟鐧岀棁鐨 PAN-NOTCH 鎶戝埗鍓
Bristol-Myers Squibb (BMS) 鍏徃鐮旂┒鑰呴壌瀹氬嚭涓€绉嶅彛鏈 pan-Notch锛堢缁忔€у熀鍥犲骇 notch 鍚岀郴鐗╄泲鐧斤級BMS-983970锛屾嫙鐢ㄤ簬娌荤枟鐧岀棁銆侭MS-983970 瀵 Notch 1 鍜 3 鐨 IC50 鍊煎垎鍒负 5 鍜 8 nM锛屼篃鎶戝埗浜 T 缁嗚優鎬ユ€ф穻宸寸粏鑳炴€х櫧琛€鐥咃紙T-ALL锛夌粏鑳炵郴鐨勫娈栵紝IC50 涓 2 nM銆侭MS-983970 鍦ㄧ姮浣撳唴鐨 t1/2 涓 14 灏忔椂锛屼汉鑲濆井绮掍綋鍜岀姮鑲濆井绮掍綋 t1/2 鍒嗗埆涓 79 鍜 108 鍒嗛挓銆傜姮銆佺尨銆佸皬榧犲拰澶ч紶瀵 BMS-983970 鐨勫彛鏈嶇敓鐗╁埄鐢ㄥ害鍊煎垎鍒负 80%銆?4%銆?2% 鍜 42%銆侭MS-983970 娌荤枟瀵 T-ALL 鍜屽疄浣撶槫寮傜绉绘妯″瀷鐨勭枟鏁堢ǔ鍋ワ紝鏈€浣庢湁鏁堝墏閲忎负 1 mg/kg锛屾瘡鏃ュ彛鏈嶄竴娆°€傛鑽殑姣掓€т篃鍙互鎺ュ彈锛圙avai, A.V. et al 105th Annu Meet Am Assoc Cancer Res (AACR) (April 5-9, San Diego) 2014, Abst 1643锛夈€備笓鍒╂枃鐚腑浠ュ墠浠嬬粛杩囪鍖栧悎鐗 (WO 2014047374)銆
螒-鐢熻偛閰氱被浼肩墿鍏峰鎶楄绠$敓鎴愬拰鎶楄偪鐦ゆ椿鎬
闊╁浗涓€涓爺绌跺洟闃熶粙缁嶄簡涓€绉嶆柊鍨 伪-鐢熻偛閰氱被浼肩墿娌荤枟鐧岀棁鐨勭粨鏋溿€傝鍖栧悎鐗╃О涓 BJ-1301锛屾槸 伪-鐢熻偛閰氱殑涓€绉嶆皑鍩哄悺鍟剁被浼肩墿锛屽鍏舵姂鍒惰绠″舰鎴愬拰鑲跨槫鐢熼暱杩涜浜嗚瘯楠屻€傚ぉ鐒跺強鍚堟垚鎶楁哀鍖栫墿锛堝寘鎷淮鐢熺礌 E锛夐€氳繃婵€娲荤敓闀垮洜瀛愬彈浣擄紙濡傝绠″唴鐨敓闀垮洜瀛愬彈浣擄紝VEGFR锛夎€屽娲绘€ф哀锛坮eactive oxygen species锛孯OS锛変骇鐢熸姉姘у寲娲绘€э紝闅忓悗鎶戝埗琛€绠$敓鎴愶紝鎴戜滑瀵规杩涜浜嗚皟鏌ャ€傜粨鏋滆〃鏄庡悎鎴愭姉姘у寲鐗 BJ-1301 鍦ㄩ浮鑳氱粧姣涜啘灏垮泭鑶滐紙chorioallantoic membrane锛孋AM锛変腑鎶戝埗浜 VEGFR 璇卞彂琛€绠$敓鎴愬強寮傜绉绘浜鸿偤鐧 A549 缁嗚優 CAM 鐨勮偪鐦ょ敓闀裤€傛椿浣撳唴璇曢獙涓 VEGFR 璇卞彂鍜岃偪鐦よ绠$敓鎴愬強鐢熼暱鎶戝埗鏁堝簲瓒呰繃浜嗗ぉ鐒跺強鍚堟垚瀵圭収鍓 伪-鐢熻偛閰 2,2,5,7,8-浜旂敳鍩?6-缇熻壊鐑凤紙PMC锛夊拰 SU-4312锛堜竴绉嶉叒姘ㄩ吀婵€閰舵姂鍒跺墏锛夈€傝鑽繕鎶戝埗浜 ROS 鐨勭敓鎴愶紝鍦ㄦ椿浣撳唴鎴栨椿浣撳鐨勮嵂鏁堥兘寮轰簬伪-鐢熻偛閰 鍜 PMC銆侭J-1301 骞舵湭琛ㄧ幇鍑 SU-4312 閭f牱鐨 VEGFR-2 鎶戝埗娲绘€с€傜幇宸茬‘瀹氳繖绉嶄綔鐢ㄦ柟寮忔槸鐢 NADPH 姘у寲閰剁洿鎺ユ椿鍖栧墏 12-O-鍗佸洓閰颁經娉?13-涔欓叝鎶戝埗 ROS 鐢熸垚鎵€浠嬪鐨勩€傛€讳箣锛孊J-1301 鎶戝埗浜 CAM 妯″瀷涓殑 VEGF 鍜岃偪鐦よ鍙戣绠$敓鎴愬強鑲跨槫鐢熼暱锛屽叾閮ㄥ垎浣滅敤鏂瑰紡涔熷緱浠ョ‘瀹氾紙Banskota, S. et al Exp Biol (April 26-30, San Diego) 2014, Abst 842.5锛夈€ 涓撳埄鏂囩尞涓粙缁嶄簡 BJ-1301 (WO 2013085340)銆
鎶楄灏忔澘鑽 VORAPAXAR 鑾 FDA 鎵瑰噯
FDA 鎵瑰噯浜 Zontivity锛坴orapaxar锛夌墖锛岀敤浜庡嚭鐜拌繃蹇冭剰鐥呭彂浣滄垨鎮f湁澶栧懆琛€绠$柧鐥呮偅鑰呴檷浣庡績鑴忕梾鍙戜綔銆佸崚涓€佸績琛€绠℃浜¢闄╋紝鍑忓皯鍐犺剦琛€杩愰噸寤虹殑闇€瑕併€侻erck & Co. 鏃椾笅瀛愬叕鍙 Merck Sharp & Dohme 鍑哄搧鐨 Zontivity锛屾槸鏂颁竴绫昏泲鐧介叾鈥撴椿鍖栧彈浣 1锛圥AR-1锛夋嫯鎶楀墏鐨勯涓姉琛€灏忔澘鑽€傝鑽殑澶勬柟璧勬枡鍖呮嫭鍑鸿椋庨櫓鐩稿叧鍔犳璀﹀憡锛孼ontivity 绂佺敤浜庢湁杩囧崚涓€佺煭鏆傛€х己琛€鍙戜綔鎴栭鍐呭嚭琛€鑰咃紙FDA 鏂伴椈绋匡級銆
TAISHO PHARMACEUTICAL 鍏徃鍦ㄦ棩鏈帹鍑 LUSEFI
Taisho Pharmaceutical 鍏徃鎺ㄥ嚭浜嗛€夋嫨鎬ч挔/钁¤悇绯栧崗鍚岃浆杩愯泲鐧 2锛圫GLT2锛夋姂鍒跺墏 Lusefi(R)锛堥瞾鏍煎垪鍑€锛汿S-071锛?.5 鍜 5 mg 鐗囧墏锛岀敤浜庢不鐤 2 鍨嬬硸灏跨梾銆傝浜у搧鐨勮幏鎵规牴鎹殑鏄鏃ユ湰 2 鍨嬬硸灏跨梾鎮h€呭疄鏂界殑涓€椤 III 鏈熺爺绌讹紝璇佸疄 Lusefi 鍗曡嵂娌荤枟鎴栦笌 6 绉嶅彛鏈嶉檷绯栬嵂鑱斿悎娌荤枟瀵规敼鍠勮绯栫殑鏁堟灉鏋佷匠銆傝绯栨帶鍒舵渶闀跨淮鎸佷簡 52 鍛ㄣ€侺usefi 鍦ㄦ暣涓爺绌舵湡闂磋繕琛ㄧ幇鍑鸿壇濂界殑瀹夊叏鎬с€侺usefi 灏嗙敱 Taisho Pharmaceutical 缁煎悎闄勫睘鍏徃 Taisho Toyama Pharmaceutical 鍜 Novartis Pharma 鍏徃钀ラ攢锛圱aisho Pharmaceutical 鏂伴椈绋匡級銆
鏂板瀷缁勮兒 H1/H4 鍙岄噸婵€鍔ㄥ墏娌荤枟鍙樺簲鎬х粨鑶滅値
Ora 鍜 Griffin Discoveries 鍏徃鐮旂┒浜哄憳鎶ラ亾浜 2 绉嶇粨鏋勪笉鐩稿叧缁勮兒 H1 鍜 H4 鍙岄噸鍙椾綋鎷姉鍓傦紝鐢ㄤ簬缂撹В鍙樺簲鎬х粨鑶滅値鐥囩姸浣撳緛銆備娇鐢ㄧ粨鑶滃彉搴斿師婵€鍙戞ā鍨嬶紝瀵规瘮閫夋嫨鎬 H4 鍙椾綋鎷姉鍓傦紙GD-135锛夊ゥ娲涗粬瀹氬拰娉煎凹鏉鹃緳锛堥槼鎬у鐓у墏锛夊強璧嬪舰鍓傚鐓у搧锛屾鏌ヤ簡缁勮兒 H1/H4 鍙椾綋鍙岄噸浣滅敤鎷姉鍓 GD-134 鍜 GD-136銆備娇鐢ㄧ煭璞曡崏鍙樺簲鍘熻嚧鏁忕殑闆屾€ BALB/c 灏忛紶锛岀 0 澶╁拰浣 17 澶╃粰浜堟阿姘у寲閾濆眬閮ㄦ縺鍙戝悗锛屽垎閰嶅埌 6 涓不鐤楃粍锛堟瘡缁 n = 9 鍙紱0.1% GD-134銆?.1% GD-135銆?.1% GD-136銆?.0% 娉煎凹鏉俱€?.1% 濂ユ礇浠栧畾鍜岃祴褰㈠墏锛夈€傜 18 鍜 19 澶╂瘡鏃ョ粰浜堜竴娆″眬閮ㄦ不鐤楋紝绗 20 澶╂瘡鏃ュ眬閮ㄦ不鐤 4 娆★紝绗 21 鈥 24 澶╂瘡鏃 2 娆″眬閮ㄦ縺鍙戯紝骞舵帴鍙楁瘡鏃 3 娆″眬閮ㄦ不鐤椼€傜 21鈥?4 澶╂縺鍙戝悗杩涜璇勪环锛岀 25 澶╁姝诲姩鐗┿€傚湪姝ゆā鍨嬩腑锛岄€夋嫨鎬 H4 鍙椾綋鎷姉鍓傛棤褰卞搷锛屼絾涓庢墍鏈夋按骞虫縺鍙戠浉姣旓紝 GD-134 鍜 GD-136 鏄庢樉闄嶄綆浜嗗彉搴斿師璇卞彂鍏呰锛屽潎瓒呰繃浜嗕袱绉嶉槼鎬у鐓у墏銆傛縺鍙戠粨鏉熸椂濂ユ礇浠栧畾浣挎枩瑙嗚瘎鍒嗘槑鏄鹃檷浣庛€傛€讳箣锛屽弻閲嶄綔鐢 H1/H4 鍙椾綋鎷姉鍓傛不鐤楀彉搴旀€х粨鑶滅値鍙兘浼樹簬浼犵粺鐤楁硶锛圕hapin, M.J. et al Annu Meet Assoc Res Vis Ophthalmol (ARVO) (May 4-8, Orlando) 2014, Abst 2482锛夈€
AMD 鐨勬柊鍨嬮潪缁寸敳閰哥被娌荤枟鑽槑鏄鹃檷浣 RBP4 琛€娴嗘按骞
鍝ヤ鸡姣斾簹澶у鍖荤枟涓績鐮旂┒浜哄憳璇勪环浜 BPN-3855 鐨勮嵂鍔ㄥ鍜岃嵂鏁堝锛岃繖鏄竴绉嶆柊鍨嬬淮鐢查吀绫昏榛勯唶缁撳悎铔嬬櫧-4锛圧BP4锛夋嫯鎶楀墏锛屾嫙鐢ㄤ簬娌荤枟鑰佸勾鎬ч粍鏂戝彉鎬э紙age-related macular degeneration锛孉MD锛夈€傚湪浣撳鐮旂┒涓紝BPN-3855 鍦ㄤ汉浣撱€佸ぇ榧犮€佺姮鍜屽皬榧犺倽寰矑浣撲腑琛ㄧ幇鍑鸿壇濂界殑浠h阿绋冲畾鎬с€傚湪闆勬€ Sprague-Dawley 澶ч紶涓紝闈欒剦鍗曞墏閲忎娇鐢 BPN-3855 (0.5 mg/kg) 鍚庣殑鍏ㄨ韩鎬绘竻闄ょ巼杈冧綆锛岀ǔ鎬佹椂浼拌琛ㄨ鍒嗗竷瀹圭Н杈冨皬銆傝〃瑙 t1/2 涓 6.3 灏忔椂锛屽崟鍓傞噺鍙f湇鐢ㄨ嵂 (5 mg/kg) 鐨勭敓鐗╁埄鐢ㄥ害涓 31%锛岃€岀 7 娆$敤鍚庣殑鐢熺墿鍒╃敤搴︿负 43%銆傚崟娆″拰澶氭鍙f湇鐢ㄨ嵂鍚庢湭鍦ㄥ翱娑蹭腑妫€鍑 BPN-3855銆傝瀵熷埌琛€娴 RBP4 闄嶄綆涓 BPN-3855 娴撳害鍗囬珮涔嬮棿瀛樺湪鑹ソ鐩稿叧鎬с€傛€讳箣锛屼笉鍚岀粨鏋勭被鍨嬬殑 RBP4 鎷姉鍓傜湅浼奸兘鍙壇濂借€愬彈锛屽苟浣胯娴 RBP4 姘村钩鏄庢樉闄嶄綆锛屽€煎緱杩涗竴姝ョ爺绌讹紙Racz, B. et al Annu Meet Assoc Res Vis Ophthalmol (ARVO) (May 4-8, Orlando) 2014, Abst 1955锛夈€
鐨川鎶戝埗绱犺鐢熺墿鍦ㄨ瘯楠屾€ CNV 涓睍鐜版綔鍔
绉戝瀹朵滑鎶ュ憡浜 SMD-02-1001锛圫irenas Marine Discovery 鍏徃锛夌殑娲讳綋澶栧拰娲讳綋鍐呮暟鎹紝杩欑鐨川鎶戝埗绱 A 琛嶇敓鐗╂嫙鐢ㄤ簬娌荤枟鑴夌粶鑶滄柊琛€绠$敓鎴愶紙CNV锛夈€傚湪娲讳綋澶栫爺绌朵腑锛岀敤鑽 HUVEC 缁嗚優杩涜澶勭悊浠ヨ瘎浼板娈栵紝鎶戝埗浣滅敤鐨 IC50 涓 4.9 nM銆係MD-02-1001 瀵 11 涓粏鑳炵郴锛堝寘鎷汉鎴愮氦缁寸粏鑳炪€佽绠″钩婊戣倢鍜岀櫧缁嗚優锛夌殑閫夋嫨鎬ф瘮瀵 HUVEC 缁嗚優鐨勯€夋嫨鎬 > 1000 鍊嶃€傛鑽繕鍦ㄤ綋澶栨姂鍒朵簡钀屽彂琛€绠″舰鎴愶紝鍏朵綔鐢ㄤ笌琛€绠″唴鐨敓闀垮洜瀛愬彈浣 (VEGF) 鎴 VEGF 鍙椾綋婵€閰剁洿鎺ユ姂鍒舵棤鍏炽€傛椿浣撳唴鐮旂┒涓紝缁欐哀璇卞彂鏂扮敓骞间粩瑙嗙綉鑶滅梾鍙樻ā鍨嬪崟娆℃敞灏勮鑽紝鍓傞噺鑼冨洿鏄 0.001 鈥 10 mcM銆傝鑽苟鏈瑙嗙綉鑶滄柊鐢熻绠″舰鎴愭樉绀哄嚭鎶戝埗浣滅敤锛屼絾浼间箮浠ユ祿搴︿緷璧栨柟寮忓噺灏戜簡琛€绠¢棴濉炪€傛澶栵紝鐜荤拑鑶滄崯浼ゆā鍨嬩腑锛孲MD-02-1001 (0.001-10 mcM) 娌荤枟鏄庢樉浠ユ祿搴︿緷璧栨柟寮忕缉灏忎簡鐥呭彉浣撶Н锛?0 nM 鏃剁缉灏 3/5锛?0 mcM 鏃剁缉灏 2/3銆傝鑽繕鏄剧ず鍑鸿劚闈舵晥搴旓紝鍦ㄨ倽寰矑浣撲腑绋冲畾锛屾彁绀鸿嵂鐞嗗鎬ц川涓嶉敊銆係MD-02-1001 鏈夋湜鎴愪负鑰佸勾鎬х浉鍏抽粍鏂戝彉鎬х殑涓€鏉″叏鏂版不鐤楃瓥鐣ワ紝鍊煎緱杩涗竴姝ョ爺绌讹紙Caballero, S. et al Annu Meet Assoc Res Vis Ophthalmol (ARVO) (May 4-8, Orlando) 2014, Abst 4955锛夈€
TAKEDA 鍏徃鐨勭淮澶氱彔鍗曟姉鑾 FDA 鎵瑰噯
FDA 鎵瑰噯浜咵ntyvio(TM)锛堢淮澶氱彔鍗曟姉锛寁edolizumab锛夋不鐤椾腑閲嶅害娲诲姩鎬ф簝鐤℃€х粨鑲犵値锛圲C锛夊強鍏嬬綏鎭╃梾锛圕D锛夛紝瀵硅薄涓虹毊璐ㄧ被鍥洪唶銆佸厤鐤皟鑺傚墏鎴栬偪鐦ゅ潖姝诲洜瀛愭姂鍒跺墏娌荤枟鏃犳晥鐨勬偅鐥呮垚浜恒€傜 0銆? 鍜 6 鍛ㄩ潤鑴夌粰浜 Entyvio 300 mg锛岄殢鍚庢瘡 8 鍛ㄧ敤鑽竴娆°€俆akeda 鍏徃浜 2013 骞 6 鏈堟彁浜や簡 Entyvio 鐨 BLA銆傛娆$敵璇锋牴鎹殑鏄 4 椤 GEMINI III 鏈熺爺绌剁殑鏁版嵁锛堣 2013 骞 6 鏈 25 鏃ャ€婃堡妫矾閫忚嵂鐗╂柊闂汇€嬶級銆?013 骞 12 鏈堬紝璇ヨ嵂鑾峰緱鎵瑰噯鎺ㄨ崘锛孎DA 寤堕暱浜嗐€婂鏂硅嵂鐢ㄦ埛璐圭敤娉曟 (PDUFA)銆嬩紭鍏堣瘎瀹$敓鏁堟棩锛屼互鍏ㄩ潰瀹℃煡 UC 閫傚簲鐥囧強 CD 閫傚簲鐥囷紙瑙 2013 骞 12 鏈 10 鏃ュ拰 2013 骞 12 鏈 30 鏃ャ€婃堡妫矾閫忚嵂鐗╂柊闂汇€嬶級銆侲ntyvio 浜 3 鏈堜唤鑾峰緱 EMA 浜虹敤鑽搧濮斿憳浼氾紙CHMP锛夎偗瀹氭€ф剰瑙侊紝鐢ㄤ簬娌荤枟涓噸搴︽椿鍔ㄦ€ UC 鍜 CD锛堣 2014 骞 3 鏈 25 鏃ャ€婃堡妫矾閫忚嵂鐗╂柊闂汇€嬶級锛圱akeda Pharmaceutical 鏂伴椈绋匡級銆
FDA 鎵瑰噯杈惧反涓囨槦娌荤枟缁嗚弻鎬х毊鑲ゅ拰鐨偆缁撴瀯鎰熸煋
FDA 鎵瑰噯浜 Durata Therapeutics 鍏徃鐨 Dalvance(TM)锛堣揪宸翠竾鏄燂紝dalbavancin锛夛紝鐢ㄤ簬娌荤枟閲戦粍鑹茶憽钀勭悆鑿屽拰閰胯創閾剧悆鑿屾墍鑷寸殑鐨偆鍜岀毊鑲ょ粨鏋勬劅鏌撱€傝揪宸翠竾鏄熸槸鏍规嵁銆奆DA 瀹夊叏鍜屽垱鏂版硶妗堛€?鍗冲埢榧撳姳鎶楃敓绱犲紑鍙 (GAIN)"缂栬€屽綋閫?鎰熸煋鎬х柧鐥呰瀹氫骇鍝?鐨勯涓幏鎵硅嵂鐗┿€傝鑽皢闈欒剦杈撴敞 1000 mg锛? 鍛ㄥ悗闈欒剦浣跨敤 500 mg銆?014 骞 4 鏈堬紝FDA 鎶楁劅鏌撹嵂鐗╅【闂鍛樹細寤鸿杈惧反涓囨槦鐢ㄤ簬杩欎簺閫傚簲鐥囷紙瑙 2014 骞 4 鏈 1 鏃ャ€婃堡妫矾閫忚嵂鐗╂柊闂汇€嬶級銆侲MA 鍦ㄥ幓骞村勾搴曞彈鐞嗕簡杈惧反涓囨槦鐨 MAA 鍚庡睍寮€璇勫锛堣 2013 骞 12 鏈 24 鏃ャ€婃堡妫矾閫忚嵂鐗╂柊闂汇€嬶級锛團DA 鏂伴椈绋垮拰 Durata Therapeutics 鏂伴椈绋匡級銆
FDA 鎵瑰噯 EPANOVA 娌荤枟楂樼敇娌逛笁閰鐥
FDA 鎵瑰噯浜 Epanova(R)锛埾?3-缇ч吀锛変綔涓烘不鐤楅噸搴﹂珮鐢樻补涓夐叝琛€鐥囨垚浜虹殑楗杈呭姪銆侫straZeneca 鍏徃鍒嗛儴 Omthera Pharmaceuticals 浜 2013 骞 7 鏈堟彁浜や簡 NDA锛堣 2013 骞 7 鏈 10 鏃ャ€婃堡妫矾閫忚嵂鐗╂柊闂汇€嬶級銆侫straZeneca 鍏徃璁″垝鍦ㄥ叾浠栧競鍦轰负姝ら€傚簲鐥囨彁浜や笂甯傜敵璇凤紝灏嗗紑灞 III 鏈熺爺绌讹紙EpaNova 鍑忚交楂樼敇娌逛笁閰鐥囬珮 CV 椋庨櫓鎮h€呯殑浠栨眬娈嬬暀椋庨櫓鐨勭粨灞€鐮旂┒锛汣linicalTrials.gov 鏍囪瘑鍙 NCT02104817锛夛紝妫€鏌 Epanova 涓庝粬姹€绫昏嵂鐗╃殑鍚堢敤銆傞璁¤瀹為獙灏嗕簬 2014 骞 5 鏈堝紑濮嬶紝灏嗘嫑鍕 28890 渚嬫湁鍔ㄨ剦绮ユ牱纭寲蹇冭绠$柧鐥呴闄╃殑鎮h€呫€傝繖椤硅瘯楠岀殑鏁版嵁鏈夋湜涓烘敮鎸佸紑鍙 蠅-3-缇ч吀涓庝粬姹€绫昏嵂鐗╃殑鍥哄畾鍓傞噺澶嶆柟鑽彁渚涙敮鎸侊紙AstraZeneca 鏂伴椈绋匡級銆
涓栫晫 MS 鏃ワ細骞茬粏鑳炵枟娉曘€佸皬鍒嗗瓙鍜岀敓鐗╂爣璁扮墿鐨勬柊杩戝彂鏄
浠 2009 骞村紑濮嬶紝澶氬彂鎬х‖鍖栧浗闄呰仈鐩燂紙MSIF锛夊強鍏舵垚鍛 MS 鍗忎細姣忓勾缁勫姙涓€娆?涓栫晫 MS 鏃?锛岃繖涓€杩愬姩鏃ㄥ湪鎻愰珮鍏ㄧ悆瀵瑰鍙戞€х‖鍖栵紙MS锛夌殑鎰忚瘑銆傚皢鍦ㄥ叏鐞冭寖鍥翠妇鍔炲悇绉嶆椿鍔紝鍏虫敞鐨勪富棰樻槸娓犻亾锛岃繖灏辨槸璇翠笉浠呰鏈夊缓绛戝満鍦扮殑鐗╃悊娓犻亾锛岃繕瑕佹湁鑽墿銆佷俊鎭拰娌荤枟鐨勬笭閬擄紝浠ュ強涓庢棤 MS 鎮h€呯浉鍚岀殑绀句細鍜岀粡娴庢満浼氥€ 璇ョ梾鏄腑鏋㈢缁忕郴缁熺殑涓€绉嶆參鎬х値鐥囨€х柧鐥咃紝鐗圭偣鏄劚楂撻灅鍜岀缁忛€€琛屾€у彉锛岀棁鐘朵赴瀵屽鏍凤紝涓ラ噸绋嬪害杞婚噸涓嶄竴銆傝鐥呯殑鍙戠敓閫氬父濮嬩簬绁炵粡绯荤粺鍔熻兘闅滅鍙戜綔锛屽姞閲嶇殑甯歌鐥囩姸鍖呮嫭楹绘湪銆佸埡鐥涖€佹棤鍔涖€佸钩琛″彈鎹熴€佽鍔涙ā绯娿€佸瑙嗐€佺湬鏅曞強鑶€鑳辨垨鑲犻亾鍔熻兘闅滅銆備笘鐣屽崼鐢熺粍缁囦及璁″叏鐞冩湁 200 鐧句竾浜烘偅鏈 MS銆 鎴戜滑鍦ㄤ笅鏂囨姤閬撲簡灏忓垎瀛愬拰骞茬粏鑳炴不鐤 MS 璇曢獙妯″瀷涓殑鏈€鏂板枩浜虹粨鏋滐紝骞堕壌瀹氬嚭鍖哄埆 MS 澶嶅彂鏈熷拰缂撹В鏈熺殑鐢熺墿鏍囪鐗┿€
骞茬粏鑳炵枟娉曡鍙戠梾姣 MS 妯″瀷鐨勭缁忔仮澶
灏忛紶 MS 妯″瀷涓 CNS 鎸佺画鐥呮瘨鎰熸煋璇卞彂鐐庣棁浠嬪鑴遍珦闉橈紝鑴婇珦鍐呯Щ妞嶄汉鑳氬共缁嗚優婧愭€х缁忓墠浣撶粏鑳烇紙hNPC锛変笌鎸佷箙鐨勪复搴婃仮澶嶇浉鍏炽€傜敤灏忛紶鑲濈値鐥呮瘨 JMH 姣掓牚鎰熸煋灏忛紶锛岄€犳垚鍚庤偄楹荤椆銆佽劚楂撻灅鍜岀缁忕値鐥囥€俬NCP 娌荤枟涔嬪悗锛屼复搴婄柧鐥呬弗閲嶇▼搴﹀噺杞伙紝绉绘鍚 6 鍛ㄤ互鍚庤繍鍔ㄦ妧鑳芥敼鍠勩€俬NPC 浣跨Щ妞嶅悗瀛樻椿浜 1 鍛ㄥ乏鍙炽€傚皬榧犺剨楂撲篃鏄剧ず绁炵粡鐐庣棁鍜岃劚楂撻灅鍑忚交銆傜煭鏆傚嚭鐜扮Щ妞嶇粏鑳炰技涔庡叿鏈夊厤鐤皟鑺備綔鐢紝鍖呮嫭鑴婇珦鍐 CD4+CD25+FOXP3+ 璋冭妭 T 缁嗚優锛涜繖浜涚粏鑳為儴鍒嗛€氳繃鍒嗘硨杞寲鐢熼暱鍥犲瓙锛圱GF锛壩?1 鍜屛?2 鑰岃捣浣滅敤锛圕hen, L. et al. Stem Cell Rep 2014, Advanced publication锛夈€
PHARMAXIS 鍏徃 LOXL2 鎶戝埗鍓傛不鐤楃氦缁村寲鍓嶆櫙灞曠幇
Pharmaxis 鍏徃鐩墠姝e湪寮€鍙戝悓宸ラ叾璧栨皑閰版哀鍖栭叾鏍疯泲鐧 2锛圠OXL2锛夋姂鍒跺墏锛屾嫙鐢ㄤ簬鍙f湇娌荤枟绾ょ淮鍖栧拰鐧岀棁锛岃繎鏃ュ湪 ATS 澶т細涓婃姤鍛婁簡杩欎竴绯诲垪灏忓垎瀛愮殑棣栨壒涓村簥鍓嶆暟鎹€ LOXL2 鏄氦缁村寲楂樺害涓婅皟鎵€鑷寸壒鍙戞€ч潪绾ょ淮鍖栫殑娼滃湪闈舵爣銆備竴绉嶇О涓 PXS-5120A 鐨勫寲鍚堢墿锛岄拡瀵 LOXL2 鐨 IC50 鍊间负 10 nM锛岄€夋嫨鎬у垎鍒槸 LOX 鍜屽叾浠栬兒姘у寲閰剁殑 200 鍊嶅拰 500 鍊嶃€傝繕鍙戠幇鑹ソ鐨勫叏韬毚闇查噺鍜 ADME銆傚湪 CCl4 璇卞彂绾ょ淮鍖栧皬榧犳ā鍨嬩腑锛孭XS-5120A 鏄湁鏁堢殑鎶楃氦缁村寲鍖栧悎鐗╋紝姝e澶╃嫾鏄熺孩鍜 伪-骞虫粦鑲岃倢鍔ㄨ泲鐧芥煋鑹叉墍瑙併€傚崥鑾遍湁绱犺鍙戣偤绾ょ淮鍖栧皬榧犱腑锛屼娇鐢 Ashcroft 璇勫垎娴嬮噺锛屼娇鐢 5 鍜 15 mg/kg 鍓傞噺鐨 PXS-5120A 鍓嶈嵂銆丩OXL2 鎶戝埗鍓 PXS-5129A锛屾槑鏄惧噺杞讳簡鑲虹氦缁村寲锛屽叾浣滅敤鍛堝墏閲忎緷璧栨€с€傝繕瑙傚療鍒拌兌鍘熻瘎鍒嗗強 伪 骞虫粦鑲岃倢鍔ㄨ泲鐧芥煋鑹查檷浣庛€傞璁″皢浜 2015 骞村紑濮 I 鏈熻瘯楠岋紙Schilter, H. et al Int Conf Am Thorac Soc (May 16-21, San Diego) 2014, Abst A6669锛夈€侟/p>
浣滆€咃細涓嶈銆€鏉ユ簮锛氭堡濮嗘.璺€廃/div>